Ushbu ishga iqtibos qilgan ishlar

2 ta ish

Ish: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

1. Catumaxomab

   James E. Frampton

   Sharh maqolaNanoparticle-Based Drug DeliveryDrugs20121 iqtibos

   ABIABI:AkademIndex/openalex/2012.review-article.000001

2. Catumaxomab: First Approval

   Yahiya Y. Syed

   Sharh maqolaCancer therapeutics and mechanismsDrugs20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.review-article.000255